



RECEIVED

NOV 04 2003

TECH CENTER 1600/2900

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/744,846		
		Filing Date	05/24/2001		
		First Named Inventor	Moreau, Jacques-Pier		
		Art Unit	1631		
		Examiner Name	Borin, Michael L.		
Sheet	1	of	2	Attorney Docket Number	00537-182002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ms	AA	ARCIDIACONO, et al., "The Use of a Long-Acting Somatostatin Analogue (Octreotide) for Prophylaxis of Acute Pancreatitis After Sphincterotomy," Endoscopy 1994; 26:715-718	
	AB	ARNOLD, et al., "Treatment of Neuroendocrine GEP Tumours with Somatostatin Analogues," Digestion 2000; 62(suppl 1)84-91	
	AC	BOTELLA, et al., "In Vivo Inhibitory Effect of Lanreotide (BIM 23014), a New Somatostatin Analog,, " Peptides 1993; 14:297-301	
	AD	BRUNAUD, et al., ["Evaluation of Somatostatin or Octreotide Efficacy," abstract in English; article in French] Ann Chir 2001;126:34-41	
	AE	COPLAN, et al., " A View on Noradrenergic, Hypothalamic-Pituitary-Adrenal Axis ...," Psychopharmacol Bull 1997; 33:193-204	
	AF	DEBAS, et al., "Somatostatin Analogue Therapy in Functioning Neuroendocrine Gut Tumors," Digestion 1993; 54(suppl 1):68-71	
	AG	DELMONT, et al., Comment in Aliment Pharmacol Ther 1995; 9:581-583	
	AH	DEMETRIADES, et al., "Effects of Lanreotide on the Healing of Small Bowel Anastomoses Following Obstructive Ileus in Rats," Colorectal Dis 2002; 4:23-27	
	AI	GAZTAMBIDE, et al., "Short- and Long-Term Effect of a Long-Acting Somatostatin Analogue, Lanreotide (SR-L) on Metastatic Gastrinoma," J. Endocrinol Invest 1999; 22:144-146	
	AJ	GOMEZ-CEREZO, et al., "Pancreatic Ascites: Study of Therapeutic Options by Analysis of Case Reports, " Am J Gastroenterol 2003; 98: 568-577	

Examiner Signature		Date Considered	11/04
--------------------	--	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



RECEIVED

NOV 04 2003

TECH CENTER 1600/2900

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	09/744,846		
		Filing Date	05/24/2001		
		First Named Inventor	Moreau, Jacques-Pier		
		Art Unit	1631		
		Examiner Name	Borin, Michael L.		
Sheet		of		Attorney Docket Number	00537-182002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mrj	AK	JAROSZ, et al., ["A Case of Ascites in the Course of Acute Pancreatitis," abstract in English; article in Polish] Pol Arch Med Wewn 1997; 97:56-61	
	AL	JENKINS, et al., "Review Article: the Relative Effectiveness of Somatostatin and Octreotide Therapy in Pancreatic Disease," Aliment Pharmacol Ther 1995; 9:349-361	
	AM	JENKINS, et al., Letter to Editor re Sancho, et al. [Cite No. AR], in Br J Surg 1995; 82:1576	
	AN	MATON, P.N., "Expanding Uses of Octreotide," Baillieres Clin Gastroenterol 1994; 8:321-337	
	AO	McKAY, et al., "A Randomized, Controlled Trial of Octreotide in the Management of Patients with Acute Pancreatitis," Int J of Pancreatol 1997; 21:13-19	
	AP	MILLER, et al., "Failure of Somatostatin or an Analog to Promote Closure of End Pancreatic Fistulae," Int J Pancreatol 1989; 4:65-72	
	AQ	NWARIKU, et al., "Is Octreotide Beneficial Following Pancreatic Injury," Am J Surg 1995; 170:582-585	
	AR	SANCHO, et al., "Randomized Double-Blind Placebo-Controlled Trial of Early Octreotide in Patients with Postoperative Enterocutaneous Fistula," Br J Surg 1995; 82:638-641	
	AS	UHL, et al., "The Role of Octreotide and Somatostatin in Acute and Chronic Pancreatitis," Digestion 1999; 60(suppl 2)23-30	
mn			

Examiner Signature		Date Considered	06/04
--------------------	--	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.